American Society of Clinical Oncology

SHERPA: White

People

  1. Pfister
    Pfister
  2. Haque
    Haque
  3. Sherman
    Sherman
  4. Baum
    Baum
  5. Baxi
    Baxi
  6. Ghossein
    Ghossein
  7. Ho
    Ho
  8. Lee
    Lee
  9. Mechalakos
    Mechalakos
  10. Ng
    Ng

Groups

  1. Department of Medicine (6)
  2. Head and Neck Service (6)
  3. Solid Tumor Oncology Division (6)
  4. Neuroradiology Service (2)
  5. Radiology, Department of (2)
  6. Surgery (2)
  7. Survivorship Research (2)
  8. Cardiology (1)
  9. Center for Pancreatic Cancer Research (1)
  10. Division of Subspecialty Medicine (1)
Search Within
  1. "2011"
  2. "David Pfister"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
Groups
  1. Department of Medicine (6)
  2. Head and Neck Service (6)
  3. Solid Tumor Oncology Division (6)
  4. Neuroradiology Service (2)
  5. Radiology, Department of (2)
  6. Surgery (2)

More Groups

People
  1. David Pfister (6)
  2. Eric Sherman (2)
  3. Sofia Haque (2)
  4. Alan Ho (1)
  5. Ashok Shaha (1)
  6. Brynna Lipson (1)

More People

Years
  1. 2011 (6)
Publications
  1. Journal of Clinical Oncology (6)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of VEGF trap in patients with radioactive iodine (RAI)-refractory thyroid carcinoma
    Meeting Abstract

    Sherman, E. J.; Ho, A. L.; Haque, S.; Tuttle, R. M.; Ghossein, R. A.; Schòˆder, H.; Baum, M. S.; Kelly, K.; Chen, A. P.; Shaha, A. R.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Phase II study of chemoradiation plus bevacizumab (BV) for locally/regionally advanced nasopharyngeal carcinoma (NPC): Preliminary clinical results of RTOG 0615
    Meeting Abstract

    Lee, N. Y.; Zhang, Q. E.; Garden, A. S.; Kim, J. J.; Pfister, D. G.; Mechalakos, J.; Hu, K.; Le, Q.; Glisson, B. S.; Chan, A. T. C.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m(2) for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Meeting Abstract

    Fury, M. G.; Sherman, E. J.; Lisa, D. M.; Agarwal, N.; Algazy, K. M.; Brockstein, B.; Langer, C. J.; Lim, D.; Mehra, R.; Rajan, S. K.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Coordination of care: Lessons learned from a pilot study in head and neck cancer
    Meeting Abstract

    Baxi, S. S.; Monether, C.; Wong, R. J.; Miransky, J.; Pfister, D. G.; Kelvin, J. F.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • 2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer
    Journal Article

    Azzoli, C. G.; Temin, S.; Aliff, T.; Baker, S. Jr; Brahmer, J.; Johnson, D. H.; Laskin, J. L.; Masters, G.; Milton, D.; Nordquist, L.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
    Journal Article

    Kurzrock, R.; Sherman, S. I.; Ball, D. W.; Forastiere, A. A.; Cohen, R. B.; Mehra, R.; Pfister, D. G.; Cohen, E. E. W.; Janisch, L.; Nauling, F.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save